Sex differences in COPD slow to be recognized, treated

**BY NEIL OSTERWEIL**  
*MDedge News*

When Sigmund Freud claimed that “anatomy is destiny” he was referring to anatomical sex as a determinant of personality traits.

That notion has been widely discredited, but Freud appears to be inadvertently right in one respect: When it comes to chronic obstructive pulmonary disease (COPD), anatomy really is destiny, and sex may be as well, pulmonary researchers say.

There is a growing body of evidence to indicate that COPD affects men and women differently, and that men and women with COPD require different clinical management. Yet women are often underdiagnosed or misdiagnosed, partly because of poorly understood sex differences, but also because of cultural biases.

But before plunging any farther into the weeds, it’s important to define terms. Although various investigators have used the terms “sex” and “gender” interchangeably, sex is the preferred term when referring to biological attributes of individual patients, while gender refers to personal identity.

These distinctions are important, contended Amik Sodhi, MBBS, MPH, from the division of allergy, pulmonology, and critical care medicine.

Pneumonia decision tool reduces deaths in ED patients

**BY PAM HARRISON**

The use of an electronic clinical decision support tool called “ePNa” reduced severity-adjusted, 30-day, all-cause mortality by 38% across 16 community hospitals in Utah, compared with predeployment levels, a 3-year, pragmatic, cluster-controlled study shows.

“We designed the ePNa specifically to require minimal input from the clinician so everything it does is already in the electronic medical record,” Nathan Dean, MD, University of Utah, Salt Lake City, told this news organization.

“So it’s actually putting the guideline recommendations into effect for physicians so that they can make better decisions by having all this information – it’s a comprehensive best practice kind of tool where best practices are likely to make the biggest difference for patients with a high severity of illness,” he added.

The study was published online in the American Journal of Respiratory and Critical Care Medicine (2022 Mar 7. doi: 10.1164/rccm.202109-2092OC).
Knowing eosinophils count is our
EOSINOPHILOSOPHY
WHAT’S YOURS?

At GSK, we believe eosinophils count for a lot. They play a role not only in disease, but also in health—and we are committed to better understanding their potential impact on patients’ lives.

**In health**
Eosinophils may contribute to overall health and immunoregulation\(^1\)\(^-\)\(^3\)

**In disease**
Eosinophils contribute to inflammation and organ damage or dysfunction\(^2\)\(^-\)\(^3\)

**In diagnosis and treatment decisions**
Blood and/or tissue eosinophils can serve as an important biomarker in clinical practice\(^4\)\(^-\)\(^11\)

References:
Knowing eosinophils count is our

EOSINOPHILOSOPHY

In health
Eosinophils may contribute to overall health and immunoregulation 1-3

In disease
Eosinophils contribute to inflammation and organ damage or dysfunction 2,3

In diagnosis and treatment decisions
Blood and/or tissue eosinophils can serve as an important biomarker in clinical practice 4-11

WHAT'S YOURS?

At GSK, we believe eosinophils count for a lot. They play a role not only in disease, but also in health—and we are committed to better understanding their potential impact on patients' lives.

Discover more about the important role of eosinophils at EOScounts.com


Trademarks are owned by or licensed to the GSK group of companies.
Guideline-based tool

The ePNa makes use of pneumonia guidelines of 2007 and 2019 from the American Thoracic Society/Infectious Disease Society of America. The system was deployed into six geographic clusters of 16 Intermountain hospital EDs at 2-month intervals between December 2017 and November 2018. Simultaneous deployment was impractical, as implementation of the tool takes education, monitoring, and feedback that can be facilitated by focusing on only a few hospitals at a time.

The decision support tool gathers key patient indicators including age, fever, oxygen saturation, vital signs, and laboratory and chest imaging results to offer recommendations on care, including appropriate antibiotic therapy, microbiology studies, and whether a given patient should be sent to the intensive care unit, admitted to hospital, or safely discharged home.

Researchers investigated a total of 6,848 patients, of whom 4,536 were managed for pneumonia before the ePNa was deployed and 2,312 after deployment. The median age of patients was 67 years (interquartile range, 50–79 years). Roughly half were female and almost all were White. “Observed 30-day all-cause mortality including both outpatients and inpatients was 8.6% before deployment versus 4.8% after deployment of ePNa,” Dr. Dean and colleagues reported.

Adjusted for severity of illness, the odds ratio for lower mortality post-ePNa launch was 0.62 (95% confidence interval, 0.49–0.79; P < .0010) “and lower mortality was consistent across hospital clusters.”

Compared with patients who were discharged home, reductions in mortality were greatest in patients who were directly admitted to the medical floor or safely sent to the intensive care unit relative to hospital ward admission but who were discharged home from the ED. “This was an unexpected finding,” Dr. Dean observed. However, as he explained, the authors reviewed 25% of randomly selected patients who fell into this subgroup and discovered that the ePNa tool was used in only about 20% of patients “– so doctors did not use the tool in the majority of this group.”

In addition, some of these patients declined hospital admission, so the doctors may have recommended that they be admitted but the patients said no. “The hypothesis here is that if they had been admitted to the hospital, they may have had a lower mortality risk,” Dr. Dean said.

Noticeable changes

Another noticeable change following the introduction of the ePNa tool was that guideline-concordant antibiotic prescribing increased in the 8 hours after patients presented to the ED, from 79.5% prior to the tool’s launch to 87.9%, again after adjusting for pneumonia severity (P < .001). Use of broad-spectrum antibiotics was not significantly different between the two treatment intervals, but administration of antibiotics active against methicillin-resistant Staphylococcus aureus dropped significantly between the two treatment intervals (P < .001). And the mean time from admission to the ED to the first antibiotic taken was

Both 30-day mortality and 7-day secondary hospital admission were higher among patients the tool recommended for hospital ward admission but who were discharged home from the ED. “This was an unexpected finding,” Dr. Dean observed. However, as he explained, the authors reviewed 25% of randomly selected patients who fell into this subgroup and discovered that the ePNa tool was used in only about 20% of patients “– so doctors did not use the tool in the majority of this group.”

In addition, some of these patients declined hospital admission, so the doctors may have recommended that they be admitted but the patients said no. “The hypothesis here is that if they had been admitted to the hospital, they may have had a lower mortality risk,” Dr. Dean said.

Noticeable changes

Another noticeable change following the introduction of the ePNa tool was that guideline-concordant antibiotic prescribing increased in the 8 hours after patients presented to the ED, from 79.5% prior to the tool’s launch to 87.9%, again after adjusting for pneumonia severity (P < .001). Use of broad-spectrum antibiotics was not significantly different between the two treatment intervals, but administration of antibiotics active against methicillin-resistant Staphylococcus aureus dropped significantly between the two treatment intervals (P < .001). And the mean time from admission to the ED to the first antibiotic taken was...
Most health care providers are comfortable recommending palliative care (PC) for their patients with interstitial lung disease (ILD), but most do so at the time of disease progression, rather than diagnosis, based on a survey of 128 clinicians.

ILD is associated with a high mortality rate and profound symptoms that contribute to poor quality of life, Rebecca A. Gersen, MD, of Johns Hopkins University, Baltimore, and colleagues wrote.

"Nevertheless, there is often a lack of preparedness for death by both patients and providers, contributing to increased distress," they said.

Clinician perspectives on the use of PC for ILD patients have not been well studied, although PC is not limited to end-of-life care and is recommended for ILD patients by professional organizations, including the American Thoracic Society. "PC is successful in improving breathlessness in chronic lung disease and can increase survival."

In a study published in the journal CHEST® (2022 Mar 16. doi: 10.1016/j.chest.2022.03.009), the researchers surveyed health care providers at 68 Pulmonary Fibrosis Foundation centers across the United States. The survey was sent and collected by email and a restricted social media platform. A total of 128 providers from 34 states completed the survey between October 2020 and January 2021. Of these, 61% were physicians, and 67% identified as White.

"There is often a lack of preparedness for death by both patients and providers, contributing to increased distress."

Overall, 95% of the respondents agreed or strongly agreed that addressing advance directives is important, but only 66% agreed or strongly agreed that they themselves addressed advance directives in the outpatient ILD clinic setting. A greater number (91%) agreed or strongly agreed that they had a high level of comfort in discussing prognosis, while 88% agreed or strongly agreed that they felt comfortable assessing a patient's readiness for and acceptance of PC. Approximately two-thirds (67%) agreed or strongly agreed that they use PC services for ILD patients. There were no significant differences in responses from clinicians who had more than 10 years of experience and those who had less.

Of the providers who referred patients to PC, 54% did so at objective disease progression, and 80% did so at objective and/or symptomatic progress; 2% referred patients to PC at initial ILD diagnosis.

**Lack of resources**

Health care providers who reported that they rarely referred patients to palliative care were significantly more likely to cite a lack of local PC options (P < .01). Those who rarely referred patients for PC also were significantly less likely to feel comfortable discussing prognoses or advance directives in the ILD clinic (P = .03 and P = .02, respectively). Among the 23% of respondents who reported that they rarely referred patients, 66% said they did not have PC at their institution.

"In addition to understanding and addressing barriers to care, educational resources may be key to improving PC delivery to the ILD population," the researchers wrote.

The study findings were limited by several factors, including voluntary participation, lack of a validated questionnaire, and use of self-reports, which may not reflect physicians' actual practice, the researchers noted. Other limitations include the use of U.S. data only, which may not generalize to countries with different health care models.

However, the results were strengthened by the use of data from providers at a range of institutions across the United States and by the high overall survey response rate, the researchers said.

"While ILD providers reassuringly demonstrate knowledge and interest in PC involvement, no current system exists to facilitate and monitor response to referral," they noted.

"Future research is desperately needed to address barriers to the provision of PC in order to enhance access to a critical service in the management and care of patients with ILD."

The study was supported by the National Heart, Lung, and Blood Institute. The researchers disclosed no relevant financial relationships.
at the University of Wisconsin–Madison.

“Sex is essentially a biologic construct, so it’s got to do with the sex chromosomes, the genetics of that person, and it refers to the anatomic variations that can change susceptibility to different diseases,” she said in an interview.

An example of sex differences or “sexual dimorphism” can be found in a recent meta-analysis of sex-based genetic associations by Megan Hardin, MD, MPH, from Brigham and Women’s Hospital in Boston and colleagues (Am J Respir Cell Mol Biol. 2017 Mar;56[3]:332-41).

They reported that CELSR1, a gene involved in fetal lung development, was expressed more among women than among men and that a single nucleotide polymorphism in the gene was associated with COPD among women smokers, but not among men smokers.

The finding points to a potential risk locus for COPD in women, and could help shed light on sexual dimorphism in COPD, Dr. Hardin and colleagues said.

In contrast to sex, “gender is more of a psycho-social construct which can impact how diseases manifest themselves, how they are potentially managed, and what outcomes might occur for that particular disease,” Dr. Sodhi said.

She and her colleagues recently published a review of sex and gender in common lung disorders and sleep in the journal CHEST (2022 Mar 14. doi: 10.1016/j.chest.2022.03.006), where they wrote that the “influence of sex and gender is portrayed in epidemiological data, disease pathogenesis and pathophysiology, clinical manifestations, response to treatment, access to care, and health outcomes. Hence, sex and gender should be considered in all types of research, clinical practice and educational curricula.”

For example, as previously reported at the 2021 annual meeting of the American Thoracic Society, sex-specific differences in the severity of symptoms and prevalence of comorbidities in patients with COPD may point to different criteria for diagnosing cardiac comorbidities in women and men.

Those conclusions came from a retrospective analysis of data on 795 women and 1,251 men with GOLD (Global Initiative for Chronic Obstructive Lung Disease) class 1-3 disease.

The investigators looked at the patients’ clinical history, comorbidities, lung function, COPD Assessment Test (CAT) scores, and modified Medical Research Council (mMRC) dyspnea score, and found significant differences between men and women for most functional parameters and comorbidities, and for CAT items of cough, phlegm, and energy.

In logistic regression analysis, predictors for cardiac disease in men were energy, mMRC score, smoking status, body mass index, age, and spirometric lung function, but in women only age was significantly predictive for cardiac disease.

An example of gender effects on COPD differences in men and women is the increase in cigarette advertising aimed at women in the 1960s and the advent of women-targeted brands such as Virginia Slims, which in turn lead to increased smoking rates among women. In addition, in the developing world, where the sex/gender gap in COPD is narrowing, women tend to have greater exposure to wood smoke and cooking fuels in unventilated or poorly ventilated spaces, compared with men.

Increasing incidence among women

According to the Centers for Disease Control and Prevention, chronic lower respiratory diseases, primarily COPD, were the fourth-leading cause of death in women in the United States in 2018, following only heart disease, cancer, and accidents/injuries.

And as a CDC analysis of data from the 2013 Behavioral Risk Factor Surveillance System showed (Morb Mortal Wkly Rep. 2015 Mar 27;64[11]:289-95), women were more likely to report being told by a physician that they had COPD than did men (6.6%, compared with 5.4%).

Dr. Sodhi and colleagues noted that, at all time points examined from 2005 to 2014, women had a higher proportion than men of COPD hospitalizations and in-hospital deaths. They also noted that female sex is associated with a threefold risk for severe early-onset COPD, and that women with COPD have lower diffusion capacity of lungs for carbon monoxide, despite having higher predicted forced expiratory volume in 1 second, compared with men.

“Historically, COPD wasn’t a disease that was so prevalent in women. It’s been in the past 20 years that the trends have changed,” said Patricia Silveyra, PhD, MSc, ATSF, associate professor of environmental and occupational health at the Indiana University, Bloomington.

The increasing prevalence of COPD among women cannot be explained by smoking alone, she said in an interview.

“It used to be thought that it was because more women smoked, but actually a lot of women who don’t smoke can develop COPD, so it appears to be probably something environmental, but because it used to be a disease of older men, in the clinic there was also a bias to diagnose men with COPD, and women with asthma, so a lot of women went underdiagnosed,” Dr. Silveyra said.

In their review, Dr. Sodhi and colleagues noted that women with COPD “may be undiagnosed as a result of having different symptoms from those classically recognized. Reasons for underdiagnosis or a delay in diagnosis may also be due to lack of a formal evaluation with spirometry, women seeking care later in the course of disease, physician bias, or associated fatigue or depression misdirecting diagnostic strategies. Underdiagnosis may be associated with psychological distress and worse health-related quality of life.”

Although the evidence is mixed, women tend to present more frequently with the chronic bronchitis phenotype of COPD, compared with the emphysema phenotype, and women tend to have greater degrees of pulmonary function impairment when exposed to tobacco smoke, even after controlling for differences in height and weight.

“For the same amount of exposure to tobacco smoke, females are likely to develop more severe airflow limitation at an earlier age than males, and have more exacerbation,” Dr. Sodhi and colleagues wrote.

Both Dr. Silveyra and Dr. Sodhi said that reasons why men and women differ in their physiological reactions to smoke are still unknown.

Sex differences in drug responses

There is only limited evidence to indicate that women and men respond differently to various therapeutic agents, but what is clear is that more research into this area is needed, Dr. Sodhi and Dr. Silveyra said.

For example, among the few studies that have documented sex differences, one showed no sex differences in the efficacy of salmeterol/fluticasone combination therapy for reducing exacerbations or improving quality of life, whereas another showed that women were more likely than men to experience COPD symptoms or exacerbations after stopping inhaled corticosteroids, Dr. Sodhi and colleagues noted.

Both Dr. Sodhi and Dr. Silveyra emphasized the need for clinical trials that study the effects of sex on treatment outcomes in COPD, which could lead to better, more personalized therapeutic regimens that take sex and gender into account.

Dr. Sodhi and colleagues offered the following advice to clinicians: “Interaction with female patients should take into account that their symptoms may not conform to traditionally accepted presentations. Challenges exist for female patients at all levels of health care interaction and as clinicians we need to acknowledge the bias and willfully work toward recognition and elimination of unconscious and conscious bias. Empowering our patients to have frank discussions with their health care team when they perceive bias is another step to help promote equity.”

The review by Dr. Sodhi and colleagues was supported by grants from the National Institutes of Health. Dr. Sodhi and Dr. Silveyra reported having no conflicts of interest to disclose.
If a patient has certain actionable mutations, first-line immunotherapy could be:

- **Ineffective**—a study showed no response for first-line IO in patients with EGFRm NSCLC

*Phase 2, single-arm study of pembrolizumab in patients with advanced EGFRm NSCLC. 82% of enrolled patients were treatment naïve. The clinical study was stopped due to lack of efficacy after 11 of 25 planned patients were enrolled. No responses were observed (ORR was 0%) in the 10 of 11 patients treated, even in patients with PD-L1 expression ≥50%. The patient who did have a response was revealed to be EGFR wild-type upon repeat analysis. 1*

- **Sequentially harmful**—starting a TKI after IO has been shown to increase the risk of toxicity in patients with mNSCLC that harbor certain EGFR or ALK alterations

2-8†

**DON’T FORCE FIT IO IN FIRST LINE**

If a patient has certain actionable mutations, first-line immunotherapy could be:

- **Ineffective**—a study showed no response for first-line IO in patients with EGFRm NSCLC

*Phase 2, single-arm study of pembrolizumab in patients with advanced EGFRm NSCLC. 82% of enrolled patients were treatment naïve. The clinical study was stopped due to lack of efficacy after 11 of 25 planned patients were enrolled. No responses were observed (ORR was 0%) in the 10 of 11 patients treated, even in patients with PD-L1 expression ≥50%. The patient who did have a response was revealed to be EGFR wild-type upon repeat analysis. 1*

- **Sequentially harmful**—starting a TKI after IO has been shown to increase the risk of toxicity in patients with mNSCLC that harbor certain EGFR or ALK alterations

2-8†

**CONFIRM MUTATION STATUS AND EXPLORE THE POSSIBILITY OF TARGETED THERAPY. LEARN MORE AT KnowBeforeIO.com**

©2021 AstraZeneca. All rights reserved. US-55515 9/21

*Based on 6 studies of 3887 patients with NSCLC and EGFR sensitizing mutations, and 1 study including 345 patients with NSCLC and ALK mutations. Of the 3887 patients with EGFR mutations, 395 were treated with immunotherapy followed by EGFR TKIs. Of the 345 patients with ALK mutations, 3 were treated with immunotherapy followed by an ALK TKI. Adverse reactions, including ILD, were observed following the sequential use of IO followed by TKI therapy in patients who had actionable mutations. 2-8

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor mutation; ILD, interstitial lung disease; IO, immuno-oncology; NSCLC, non-small cell lung cancer; ORR, overall response rate; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor.

References:
Can Gram stains guide antibiotics for VA-pneumonia?

BY LOUISE GAGNON

Similar outcomes in patients with ventilator-associated pneumonia (VAP) suggest that antibiotics selected by Gram staining were noninferior to those based on guidelines and also significantly decreased the use of broad-spectrum antibiotics in this patient population.

The findings were published April 8 in JAMA Network Open (doi:10.1001/jamanetworkopen.2022.6136). The multicenter, open-label, noninferiority, randomized trial, Gram Stain-Guided Antibiotics Choice for VAP (GRACE-VAP), was conducted for 2 years in intensive care units (ICUs) of a dozen tertiary referral hospitals in Japan, from April 1, 2018, through May 31, 2020.

The authors noted in their paper that the 2016 clinical practice guidelines for VAP published by the Infection Diseases Society of America and the American Thoracic Society recommend antibiotic agents active against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa as an empirical treatment. Adherence to these guidelines may lead to overuse of broad-spectrum antibiotic agents and could be associated with the accelerated emergence of antimicrobial-resistant organisms, the authors postulated.

The study sought to answer the question: Can Gram staining be used as an alternative to established guidelines to direct antibiotic use – thereby curbing the use of broad-spectrum antibiotics – without compromising patient safety and clinical outcomes?

A total of 206 patients, with a mean age of 69, took part in the study. The same number of patients were assigned to each arm. Patients aged 15 years or older with a VAP diagnosis and a modified Clinical Pulmonary Infection Score of 5 or higher were included.

Investigators reported that 79 patients (76.7%) responded to antibiotics in the Gram stain–guided group and 74 (71.8%) responded in the guideline–based group (risk difference, 0.05; 95% confidence interval, −0.07 to 0.17; P = .991, for noninferiority).

There was a decrease in antipseudomonal agent use comparing the Gram stain–guided group with the guideline–based group (30.1%; 95% CI, 21.5% to 39.9%; P = .001). There was also a decrease in anti-MRSA agents in the Gram stain–guided group, compared with the guideline–based group (38.8%; 95% CI, 29.4% to 48.9%; P < .001).

The 28-day cumulative incidence of mortality was 13.6% (n = 14) in the Gram stain–guided group vs. 17.5% (n = 18) in the guideline–based group. Escalation of antibiotics according to culture results was performed in seven patients (6.8%) in the Gram stain–guided group and in one patient (1.0%) in the guideline-based group. No significant differences in study arms were observed on other measures, such as ICU-free days, ventilator-free days, and adverse events.

The authors concluded that their findings support the use of Gram staining as a strategy to manage infectious diseases and contain the development of multidrug-resistant organisms (MDROs) in the setting of critical care.

“In the GRACE-VAP trial, we used the time-honored Gram stain technique as part of the daily management of infectious diseases. We believe that the trial results are acceptable and have the potential to change the strategy of antibiotic choice worldwide,” the authors wrote.

Benjamin D. Galvan, MLS(ASCP), CIC, an infection preventionist with a professional background in clinical microbiology, noted that Gram staining is more accessible and significantly less costly than the rapid polymerase chain reaction testing certain institutions use to rapidly identify MDROs to help tailor therapy.

But one of the pitfalls with relying on Gram stain collection to guide antibiotic use is that it is operator dependent and subject to extrinsic factors, like prior antibiotic use, he pointed out.

“If it is not collected, set up, and read properly, the Gram stain is not going to necessarily be reliable” said Mr. Galvan, also a member of the national communications committee for the Association for Professionals in Infection Control and Epidemiology. He added that the sample in the was not representative of institutions dealing with elevated rates of multidrug resistance.

“Even from their own results, they were looking at hospitals that have a low rate of multidrug resistance,” he said. “It was not clear if MRSA or Staphylococcus aureus was identified in significant quantities upon review, and they recognized a lower-than-expected number of isolates of Pseudomonas aeruginosa.”

Establishing antibiotic treatment from the results of Gram-stain collection may not be sufficiently comprehensive, he said.

“Generally speaking, basing it (antibiotic therapy) solely on the result of a Gram stain is not looking at the whole picture,” said Mr. Galvan, noting that the 2016 IDSA guidelines call for an evaluation of the clinical status, including risk, of the individual patient, as well as locally available antibiotic resistance data.

Moreover, the evidence-based IDSA guidelines are in place to help address the issue of antimicrobial resistance trends, already recommending tailoring empiric antibiotic therapy based upon the levels of resistance in the local population, according to Mr. Galvan.

While the study suggests that this Gram-stain–driven tailoring of empiric antibiotic therapy may be noninferior to current guidelines in health care settings with low MDRO rates, its utility may not be suitable in hospitals that are already dealing with high rates of MDROs, such as Pseudomonas aeruginosa and Acinetobacter baumannii, or severe clinical cases of VAP, Mr. Galvan explained.

The researchers and Mr. Galvan disclosed no relevant financial relationships.

David Bowton, MD, FCCP, comments: The GRACE-VAP trial examined the utility of employing the results from Gram-stained respiratory secretions vs. guideline-based antibiotic prescribing on clinical outcome and the use of broad-spectrum antimicrobial therapy. They found that by restricting anti-pseudomonal and anti-MRSA to patients with gram-negative rods or gram-positive cocci in clusters, respectively, there was no difference in clinical outcome 7 days after the end of therapy. The use of anti-pseudomonal and anti-MRSA antibiotics was reduced by 30% to 40%, and there was no difference in 28-day mortality.

I have several concerns that mitigate the broad applicability of these findings. The incidence of resistant organisms in sputum cultures was relatively low (< 25% overall). A numerically higher number of patients in the guideline group had received antibiotics prior to enrollment, which is a recognized predisposition to resistant organisms and higher mortality. The 28-day mortality of patients diagnosed with VAP was only 16%, which is considerably lower than most series of VAP, raising the question of how ill these patients were and the accuracy of the diagnosis of VAP. The diagnosis of VAP was based on a CPIS score of > 5. The clinical diagnosis of VAP is notoriously inaccurate, and even using a higher CPIS score of greater than 2, the ROC curve for accurate diagnosis based on quantitative cultures is little better than a coin toss (Schurink CAM et al. Intensive Care Med. 2004;30:217). While quantitative cultures are not a “gold standard” for VAP diagnosis, when antibiotics are discontinued when quantitative cultures are negative, there is no adverse impact on outcomes (Fagon J-Y, et al. Annals of Internal Medicine. 2000;132:621). If you do not have VAP, VAP therapy is unlikely to have a beneficial effect on outcome. Further, optimal interpretation of Gram–stained sputum requires rapid smearing, heat fixing, and staining of the specimen followed by ensuring that the smear is high quality (few epithelial cells with leukocytes present). These steps are not consistently ensured in most ICUs. While the authors state that the Gram-stained specimens were classified by the Miller and Jones and the Geckler schema, there are no data provided as to the quality of the collected specimens and how these data might have been used. It would be unusual for all enrolled patients to have high-quality specimens, yet no patient appears to have been excluded from randomization or analysis.
**Step test signals exercise capacity in asthma patients**

**BY HEIDI SPLETE**

**MDedge News**

The incremental step test is a highly reliable measure of exercise capacity in patients with moderate to severe asthma, based on data from 50 individuals.

Asthma patients often limit their physical exercise to avoid respiratory symptoms, which creates a downward spiral of reduced exercise capacity and ability to perform activities of daily living, wrote Renata Cléia Claudino Barbosa of the University of São Paulo and colleagues. “However, exercise training has been shown to be an important adjunctive therapy for asthma treatment that improves exercise capacity and health-related quality of life,” they wrote.

Step tests have been identified as a simpler, less-costly alternative to cardiopulmonary exercise tests to measure exercise capacity in patients with chronic obstructive pulmonary disease, but their effectiveness for asthma patients has not been investigated, the researchers said.

In a study published in Pulmonology (2022 Feb 24. doi: 10.1016/j.pulmoe.2022.02.002), the researchers recruited 50 adults with moderate or severe asthma during routine care at a university hospital. The participants had been clinically stable for at least 6 months, with no hospitalizations, emergency care, or medication changes in the past 30 days. All participants received short-acting and long-acting bronchodilators and inhaled corticosteroids. The patients ranged in age from 18 to 60 years, with body mass index measures from 20 kg/m² to 40 kg/m².

Participants were randomized to tests on 2 nonconsecutive days at least 48 hours apart. On the first day, patients completed asthma control questionnaires and lung function tests, then performed either a cardiopulmonary exercise test (CPET) or two incremental step tests (IST-1 and IST-2). On the second day, they performed the other test. Participants were instructed to use bronchodilators 15 minutes before each test. The step test involved stepping up and down on a 20–cm high wooden bench.

Overall, the peak oxygen (VO₂) uptakes were 27.6 mL/kg per minute for the CPET, 22.3 mL/kg per minute for the first IST, and 23.3 mL/kg per minute for the second IST. “The IST with better performance regarding the peak VO₂ value was called the best IST (b-IST),” and these values were used for validity and interpretability analyses, the researchers wrote.

We could send **23,000+** patients to your office to tell you how well the Philips InCourage system works.

Or you could just try it with a few of your patients. We think you—and they—will see the difference.
they said. However, "we believe that the exercise capacity, " the researchers said. The study findings were limited by several factors including the relatively small study population and the small number of male patients, which may limit generalizability to males with asthma or other asthma endotypes, the researchers said. However, the results were strengthened by the randomized design, and support the value of the IST as a cost-effective option for assessing exercise capacity, preferably with two step tests to minimize the learning effect, they said.

Additional research is needed to determine whether IST can assess responsiveness to pharmacological and nonpharmacological treatments in asthma patients, they noted. The study was supported by the Sao Paulo Research Foundation, Conselho Nacional de Pesquisa, and Coordination of Improvement of Higher Level Personnel-Brazil. The researchers had no conflicts to disclose.

Sachin Gupta, MD, FCCP, comments: Though functional capacity testing is not commonly used in the management of asthma as it is with chronic obstructive pulmonary disease, pulmonary arterial hypertension, and heart failure, it can provide rich insights into a patient’s physiology. Perhaps one day soon we will know the performance of the incremental step test in determining outcomes compared with other biomarkers.

The American Academy of Sleep Medicine is looking into the safety of melatonin. And while the assessment of the evidence is underway, the academy recommends that melatonin not be used for insomnia in adults or children. Muhammad Adeel Rishi, MD, vice chair of the public safety committee for the American Academy of Sleep Medicine, said there are important reasons to not use melatonin for insomnia until more information is available. Melatonin affects sleep, but also influences other functions. "It has an impact on body temperature, blood sugar, and even the tone of blood vessels," Dr. Rishi said. And because melatonin is available over the counter, it hasn’t been approved as a medicine by the FDA. A previous study of melatonin products, for instance, flagged problems with inconsistent doses, and prompted calls for more FDA oversight. While melatonin plays a role in setting the sleep and wake cycle, serotonin is also at work. Serotonin is involved in mood and helps with deep REM sleep. But adding serotonin in unknown amounts could be unhealthy. It can be dangerous to use a product as a medication when doses can be so off and there are unknown byproducts in it. Serotonin can influence the heart, blood vessels, and brain, and people taking medication for mood disorders could be affected by the serotonin in their sleep aid, Dr. Rishi warns.

Another worry is whether melatonin interferes with puberty in children – which is also a question researchers at the Children’s Hospital of Eastern Ontario in Ottawa are asking (Nat Sci Sleep. 2019;11:1-10). While short-term melatonin use is considered safe, the researchers reported, concerns that long-term use might delay children’s sexual maturation require more study.

Melatonin will probably need to be regulated by the FDA – especially for children – Dr. Rishi pointed out. And what place, if any, it will have for managing chronic insomnia is “a big question mark.”

**Trailblazers of the Future.**

**The CHEST Foundation 25th Anniversary Celebration Continues!**

Join us in 2022 as we navigate our next 25 years, and help us crush lung disease.

**Belmont Stakes Dinner and Auction**

Saturday, June 11

Gather with members of the chest medicine community to watch the Belmont Stakes race in New York City. The CHEST Foundation will host a live viewing of the race and an auction benefitting patient education initiatives for lung health. Patient advocates Betsy Glaser and Fred Schick will be honored for the lasting impact they have made for those living with chest diseases. All proceeds benefit the CHEST Foundation’s work in patient education and CHEST initiatives to improve patient care.

Join Us for the Belmont Stakes foundation.chestnet.org/BelmontStakes

**SLEEP MEDICINE**

**Many turn to melatonin for insomnia despite risks**

BY LAURA LILLIE

The American Academy of Sleep Medicine is looking into the safety of melatonin. And while the assessment of the evidence is underway, the academy recommends that melatonin not be used for insomnia in adults or children. Muhammad Adeel Rishi, MD, vice chair of the public safety committee for the American Academy of Sleep Medicine, said there are important reasons to not use melatonin for insomnia until more information is available. Melatonin affects sleep, but also influences other functions. "It has an impact on body temperature, blood sugar, and even the tone of blood vessels," Dr. Rishi said. And because melatonin is available over the counter, it hasn’t been approved as a medicine by the FDA. A previous study of melatonin products, for instance, flagged problems with inconsistent doses, and prompted calls for more FDA oversight.

While melatonin plays a role in setting the sleep and wake cycle, serotonin is also at work. Serotonin is involved in mood and helps with deep REM sleep. But adding serotonin in unknown amounts could be unhealthy. It can be dangerous to use a product as a medication when doses can be so off and there are unknown byproducts in it. Serotonin can influence the heart, blood vessels, and brain, and people taking medication for mood disorders could be affected by the serotonin in their sleep aid, Dr. Rishi warns.

Another worry is whether melatonin interferes with puberty in children – which is also a question researchers at the Children’s Hospital of Eastern Ontario in Ottawa are asking (Nat Sci Sleep. 2019;11:1-10). While short-term melatonin use is considered safe, the researchers reported, concerns that long-term use might delay children’s sexual maturation require more study.

Melatonin will probably need to be regulated by the FDA – especially for children – Dr. Rishi pointed out. And what place, if any, it will have for managing chronic insomnia is “a big question mark.”
The quest for a good night’s sleep: An update on pharmacologic therapy for insomnia

BY MICHAEL PELEKANOS, MD; AND OLIVER SUM-PING, MD

Insomnia is one of the most common complaints in medicine, driving millions of clinic visits each year (Table 1). It is estimated that approximately 30% of individuals report at least short-term insomnia symptoms and 10% report chronic insomnia. These rates are even higher in groups that may be more susceptible to insomnia, including women, the elderly, and those of disadvantaged socioeconomic status (Olayon MM. Sleep Med Rev. 2002;6[2]:97-111). While most patients with insomnia find their sleep difficulties self-resolve within 3 months, a substantial number of patients will find their insomnia persists for longer and require intervention (Sateia M et al. J Clin Sleep Med. 2017;13[2]:307-49).

For individuals requiring treatment, cognitive behavioral therapy for insomnia (CBT-I) is considered first-line therapy by the American Academy of Sleep Medicine for both acute and chronic insomnia. Unfortunately, obtaining CBT-I for a patient is often a challenge as the number of trained therapists offering this service is limited, resulting in long wait times or, in some cases, a complete lack of access to this treatment option. Judicious use of sedative-hypnotic medications may be a reasonable alternative for patients with insomnia who are unable to undergo CBT-I, who are still symptomatic despite undergoing CBT-I, or, in some cases, as a temporary treatment (Sateia M et al. J Clin Sleep Med. 2017;13[2]:307-49).

Current medications used to treat insomnia are listed in Tables 2 and 3, some of which carry an FDA approval to be used as a hypnotic, while others are used in an off-label manner.

Cautions abound with use of many of these medications. Common concerns include safety, particularly for elderly patients and long-term use, and the potential for developing tolerance and dependence.

Most medications that have been used for insomnia have been available for decades, but, in recent years, a new class of hypnotics has emerged. Dual orexin receptor antagonists (DORAs) are the newest class of FDA-approved medications (Table 4).

Orexin is a neuropeptide found primarily in the lateral hypothalamus and binds to the orexin 1 and orexin 2 receptors leading to a number of downstream effects, including stimulating wakefulness. Loss of orexin-generating neurons is implicated as the cause of type 1 narcolepsy, and antagonism of their effects can facilitate sleep by suppressing wakefulness. The first medication in the DORA class to be FDA-approved was suvorexant in 2014, followed by lemborexant’s FDA approval in 2019. These are both indicated for treating sleep onset and sleep maintenance insomnia and have been shown to improve both subjective and objective measures of sleep. The most common side effects reported for both suvorexant and lemborexant are headache and somnolence, with morning-after sleepiness being a frequent complaint.

In January 2022, a new medication in the DORA class named dardorexant was approved by the FDA (Table 5). Dardorexant, like its DORA counterparts, has been shown to have efficacy in improving subjective and objective markers of insomnia. This has included polysomnographic measures of wake after sleep onset and latency to persistent sleep, as well as subjective total sleep time. Importantly, in addition to positive sleep outcomes, improvements with daytime function have also been observed with this medication (Mignot E et al. Lancet Neurol. 2022;21[2]:125-39). Dardorexant’s half-life of approximately 8 hours is shorter than that of the other available DORAs, leading to fewer day-after effects. The combination of effectiveness for sleep initiation and maintenance without daytime impairment distinguishes dardorexant from the other DORAs and even other classes of sleep medication.

Safety, especially in patients age 65 and older, is an important concern with sleep medication, particularly with respect to polypharmacy, over-sedation, increased fall risk, and cognitive impairment, but dardorexant’s available safety data suggest a favorable safety profile (Zammit G et al. Neurology. 2020;94[21]:e2222-32). Dardorexant at the highest dose available, suvorexant 10-30 mg, lemborexant 5-10 mg, and dardorexant 25-50 mg.

---

**TABLE 2**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosage</th>
<th>FDA approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suvorexant</td>
<td>5-20 mg</td>
<td>2014</td>
</tr>
<tr>
<td>Lemborexant</td>
<td>5-10 mg</td>
<td>2019</td>
</tr>
<tr>
<td>Dardorexant</td>
<td>25-50 mg</td>
<td>2022</td>
</tr>
</tbody>
</table>

---

**TABLE 4**

<table>
<thead>
<tr>
<th>Dual orexin receptor antagonists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication</td>
</tr>
<tr>
<td>------------</td>
</tr>
<tr>
<td>Suvorexant</td>
</tr>
<tr>
<td>Lemborexant</td>
</tr>
<tr>
<td>Dardorexant</td>
</tr>
</tbody>
</table>
**COVID-19**

30% of infected patients found to develop long COVID

**BY RALPH ELLIS**

About 30% of COVID-19 patients developed the condition known as long COVID, University of California, Los Angeles, researchers said in a study published in the Journal of General Internal Medicine (2022 Apr 7. doi: 10.1007/s11606-022-07523-3).

The UCLA researchers studied 1,038 people enrolled in the UCLA COVID Ambulatory Program between April 2020 and February 2021 and found that 309 developed long COVID. A long-COVID diagnosis came if a patient answering a questionnaire reported persistent symptoms 60-90 days after they were infected or hospitalized. The most persistent symptoms were fatigue (31%) and shortness of breath (15%) in hospitalized participants. Among outpatients, 16% reported losing sense of smell.

The study’s findings differ from earlier research. The University of California, Davis, for example, estimated that 10% of COVID-19 patients develop long-haul symptoms. A 2021 study from Penn State University found that more than half of worldwide COVID-19 patients would develop long COVID (JAMA Netw Open. 2021;4(10):e2128568).

Part of the discrepancy can blame on the fact there is no official, widely accepted definition of long COVID. The CDC has said it means patients who experience “new, returning, or ongoing health problems 4 or more weeks after an initial infection” by the coronavirus. The UCLA study, meanwhile, included patients still having symptoms 60-90 days after infection.

Still, the UCLA research team looked at demographics and clinical characteristics in an attempt to develop effective treatments.

People with a history of hospitalization, diabetes, and higher body mass index were most likely to develop long COVID, the researchers said. “Surprisingly, patients with commercial insurance had double the likelihood of developing [long COVID] compared to patients with Medicaid,” they wrote. “This association will be important to explore further to understand if insurance status in this group is representing unmeasured demographic factors or exposures.”

Older age and socioeconomic status were not associated with long COVID in the study – a surprise because those characteristics are often linked with severe illness and higher risk of death from COVID-19. Weaknesses in the study included the subjective nature of how patients rated their symptoms and the limited number of symptoms evaluated.

“This study illustrates the need to follow diverse patient populations ... to understand the long COVID disease trajectory and evaluate how individual factors ... affect type and persistence of long COVID symptoms,” said Sun Yoo, MD, health sciences assistant clinical professor at UCLA.

---

**Experience adds up with OFEV**

ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; SSc-ILD, systemic sclerosis-associated interstitial lung disease.

**IMPORTANT SAFETY INFORMATION**

**WARNINGS AND PRECAUTIONS**

**Hepatic Impairment:** OFEV is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment. Patients with mild hepatic impairment (Child Pugh A) can be treated with a reduced dosage (100 mg twice daily). Consider treatment interruption or discontinuation for management of adverse reactions.

**Elevated Liver Enzymes and Drug-Induced Liver Injury**

- Cases of drug-induced liver injury (DILI) have been observed with OFEV treatment. In the clinical trials and post-marketing period, non-serious and serious cases of DILI were reported. Cases of severe liver injury with fatal outcome have been reported in the post-marketing period. The majority of hepatic events occur within the first three months of treatment. OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, and GGT) and bilirubin. Liver enzyme and bilirubin increases were reversible with dose modification or interruption in the majority of cases.

- In IPF studies, the majority (94%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (95%) of patients with bilirubin elevations had elevations less than 2 times ULN.

- In the chronic fibrosing ILDs with a progressive phenotype study, the majority (95%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (94%) of patients with bilirubin elevations had elevations less than 2 times ULN.

---

“Surprisingly, patients with commercial insurance had double the likelihood of developing [long COVID] compared to patients with Medicaid,” they wrote. “This association will be important to explore further to understand if insurance status in this group is representing unmeasured demographic factors or exposures.”

**Experience adds up with OFEV**

ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; SSc-ILD, systemic sclerosis-associated interstitial lung disease.

**IMPORTANT SAFETY INFORMATION**

**WARNINGS AND PRECAUTIONS**

**Hepatic Impairment:** OFEV is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment. Patients with mild hepatic impairment (Child Pugh A) can be treated with a reduced dosage (100 mg twice daily). Consider treatment interruption or discontinuation for management of adverse reactions.

**Elevated Liver Enzymes and Drug-Induced Liver Injury**

- Cases of drug-induced liver injury (DILI) have been observed with OFEV treatment. In the clinical trials and post-marketing period, non-serious and serious cases of DILI were reported. Cases of severe liver injury with fatal outcome have been reported in the post-marketing period. The majority of hepatic events occur within the first three months of treatment. OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, and GGT) and bilirubin. Liver enzyme and bilirubin increases were reversible with dose modification or interruption in the majority of cases.

- In IPF studies, the majority (94%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (95%) of patients with bilirubin elevations had elevations less than 2 times ULN.

- In the chronic fibrosing ILDs with a progressive phenotype study, the majority (95%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (94%) of patients with bilirubin elevations had elevations less than 2 times ULN.
COVID-19

One in four feel fully recovered after hospitalization

BY ROB HICKS, MBBS

In a new U.K. study of more than 2,000 patients, presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases, and published in The Lancet Respiratory Medicine (2022. doi: 10.1016/S2213-2600(22)00127-8), only one in four patients reported feeling fully well 1 year after COVID-19 hospitalization.

The researchers assessed 2,320 participants discharged from 39 U.K. hospitals between March 7, 2020, and April 18, 2021, via patient-reported outcome measures, physical performance, and organ function at 5 months and at 1 year after hospital discharge. All participants were assessed at 5 months after discharge and 807 participants (33%) completed both the 5-month and 1-year assessments.

Elevated Liver Enzymes and Drug-Induced Liver Injury (cont’d)

• In the SSc-ILD study, a maximum ALT and/or AST greater than or equal to 3 times ULN was observed in 4.9% of patients treated with OFEV.
• Patients with low body weight (less than 65 kg), patients who are Asian, and female patients may have a higher risk of elevations in liver enzymes. Nintedanib exposure increased with patient age, which may result in increased liver enzymes.
• Conduct liver function tests prior to initiation of treatment, at regular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. Measure liver function tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Dosage modifications, interruption, or discontinuation may be necessary for liver enzyme elevations.

Please see additional Important Safety Information on the following pages and accompanying Brief Summary of Prescribing Information.

See how the clinical trial data adds up at OFEVhcp.com/experience

RECOVERED continued on following page
had mechanical ventilation in hospital makes someone 32%, 50%, and 58%, respectively, less likely to feel fully recovered 1 year after COVID-19 hospitalization, the authors said. The authors said fatigue, muscle pain, physically slowing down, poor sleep, and breathlessness were most common ongoing long COVID symptoms. The total number and range of ongoing symptoms at 1 year was "striking," positively associated with the severity of long COVID, and emphasizes the "multi-system nature of long COVID."

An earlier publication from this study identified four groups or "clusters" of symptom severity at 5 months, which were confirmed by this new study at 1 year, the authors said. They reported that 20% had very severe physical and mental health impairment, 30% had severe physical and mental health impairment, 11% had moderate physical health impairment with cognitive impairment, and 39% had mild mental and physical health impairment. They added that having obesity,
reduced exercise capacity, a greater number of symptoms, and increased levels of C-reactive protein were associated with the "more severe clusters." In both the very severe and the moderate with cognitive impairment clusters, levels of interleukin-6 (IL-6) were higher when compared with the mild cluster. "The limited recovery from 5 months to 1 year after hospitalisation in our study across symptoms, mental health, exercise capacity, organ impairment, and quality-of-life is striking," the researchers noted. "In our clusters, female sex and obesity were also associated with more severe ongoing health impairments including reduced exercise performance and health-related quality of life at one year," and suggested that this potentially highlighted a group that "might need higher intensity interventions such as supervised rehabilitation," they added.

There are no specific therapeutics for long COVID, the researchers said, noting that "effective interventions are urgently required." The persistent systemic inflammation identified, particularly in those in the very severe and moderate with cognitive impairment clusters, suggested that these groups "might respond to anti-inflammatory strategies," the authors wrote. 

They warned that without effective treatments, long COVID could become a "highly prevalent new long-term condition."
COVID-19

FDA OKs COVID-19 breath test for specific settings

BY DAMIAN MCNAMARA

T he US Food and Drug Administration (FDA) has granted emergency use authorization to a first-of-its-kind test that can detect SARS-CoV-2 in the breath in less than 3 minutes. The COVID-19 Breathalyzer test (InspectIR Systems) will be available only in licensed test settings, therefore it is not currently meant for home use. That’s one reason why the impact of the test may be limited, said William Schaffner, MD. The manufacturer claims it can produce about 100 testing instruments a week; “it’s not as though they are producing 10,000,” he said. Also, the capacity is limited — each testing system can evaluate 160 breath samples per day.

“So this can’t be used at a concert or a big ball game or something like that,” said Dr. Schaffner,
Gastrointestinal Perforation (see Warnings and Precautions).

6.1 Clinical Trials Experience: Because clinical trials are conducted under strictly controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. The safety of OFEV was evaluated in over 1,000 patients, 332 patients with chronic fibrosing ILDs with a progressive phenotype, and over 280 patients with SSC-ILD. Over 200 IF patients were exposed to OFEV for more than 2 years in clinical trials. Idiopathic Pulmonary Fibrosis: OFEV was studied in three randomized, double-blind, placebo-controlled, 52-week trials. In the phase 2 Study 1 (phase 1 and phase 2: Studies 1 and 3) trials, 723 patients with IF P-IPF patients were exposed to OFEV 150 mg twice daily and 508 received placebo. The median duration of exposure was 10 months for patients treated with OFEV and 11 months for patients treated with placebo. Subjects ranged in age from 42 to 89 years (median age of 61 years) and 15% of subjects were female. The most frequent adverse reaction that led to permanent dose reduction in the patients treated with OFEV was diarrhea (1.9%) and of patients treated with placebo. No pattern was identified in the adverse events associated with dose reduction. Adverse reactions leading to permanent dose reductions were reported in 13% of OFEV-treated patients and 4% of placebo-treated patients. The most frequent adverse reaction that led to discontinuation in OFEV-treated patients was diarrhea (4%).

the postmarketing period. In the phase 2 (Study 1) trial, 57 patients with SSC-ILD received OFEV 150 mg twice daily (n=228) or placebo (n=226). Patients were to receive treatment for at least 52 weeks; individual patients were treated for up to 100 weeks. The median duration of exposure was 15 months for patients treated with OFEV and 16 months for patients treated with placebo. Subjects ranged in age from 20 to 79 years (median age of 55 years). Most patients were female (75%), Patients were mostly Caucasian (67%), Asian (25%), and Black (8%). At baseline, 49% of patients were on stable therapy with prednisone. The most frequent serious adverse events reported in patients treated with OFEV, more than placebo, were interstitial lung disease (2% vs 1% placebo), and pneumonitis (2.9% vs. 0.3% placebo). Within 52 weeks, 5 patients treated with OFEV (1.7%) and 4 patients treated with placebo (1.4%) died. There was no pattern among adverse events leading to death in either treatment arm. Adverse reactions leading to permanent dose reductions were reported in 34% of OFEV-treated patients and 4% of placebo-treated patients. The most frequent adverse reactions leading to discontinuation in OFEV-treated patients were diarrhea (6%) and nausea (2%).

Table 1: Adverse Reactions Occurring in >5% of OFEV-treated Patients and More Commonly Than Placebo in Studies 1, 2, and 3

Adverse Reaction | OFEV, 150 mg | Placebo, 150 mg |
-----------------|--------------|----------------|
Gastrointestinal disorders | 62% | 18% |
Nausea | 24% | 7% |
Abdominal pain | 10% | 6% |
Recovery disorders | 12% | 5% |
Liver enzyme elevationa | 13% | 3% |
Nervous system disorders | 5% | 5% |
Investigations | 5% | 6% |
Vascular disorders | 5% | 4% |
Hypertensionb | 5% | 4% |

Includes abdominal pain, abdominal pain upper, abdominal pain lower, and epigastric pain.

Includes gamma-glutamyltransferase increased, hepatic enzyme increased, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme abnormal, liver function test abnormal, transaminase increased, blood alkaline phosphatase increased, alkaline aminotransferase abnormal, aspartate aminotransferase abnormal, and gamma glutamyltransferase increased.

Includes hypertension, blood pressure increased, hypertensive crisis, and hypertensive cardiac disorders.

In addition, hypophosphatemia was reported in patients treated with OFEV more than placebo (1.1% vs. 0.0%). Combination with Pirfenidone: Concomitant treatment with pirfenidone was investigated in an exploratory open-label, randomized (1:1) trial of nintedanib 150 mg twice daily with or without pirfenidone and compared to nintedanib 150 mg once daily in 161 randomized patients for 12 weeks. The primary endpoint was the percentage of patients with adverse adverse events from Week 0 to Week 12. Gastrointestinal adverse events were in line with the established safety profile of each component and were experienced in 37 (70%) patients treated with pirfenidone added to nintedanib vs. 27 (53%) patients treated with nintedanib alone.

1.2 Chronic Fibrosing Interstitial Lung Diseases: A Phase 2b/3 trial of OFEV was studied in a phase 3, double-blind, placebo-controlled trial (Study 5) in which 663 patients with chronic fibrosing ILDs with a progressive phenotype were randomized to receive OFEV 150 mg twice daily (n=332) or placebo (n=331) for at least 52 weeks. At 52 weeks, the median duration of exposure was 12 months for patients treated with OFEV and 11 months for patients treated with placebo. Subjects ranged in age from 27 to 85 years (median age of 67 years). The major exclusion criteria were Child-Pugh C cirrhosis (24%) or Asian (25%). Most patients were male (54%). The most frequent serious adverse event observed in patients treated with OFEV, except diarrhea (14% vs. 8%), was a serious adverse reaction leading to death reported in 3% of patients treated with OFEV and in 3% of patients treated with placebo. No pattern was identified in the adverse events associated with death. Adverse events leading to permanent dose reductions were reported in 33% of OFEV-treated patients and 4% of placebo-treated patients. The most frequent adverse reaction that led to permanent dose reduction in the patients treated with OFEV was diarrea (16%). Adverse reactions leading to discontinuation were reported in 20% of OFEV-treated patients and 10% of placebo-treated patients. The most frequent adverse reaction that led to discontinuation in OFEV-treated patients was diarrhea (6%). The safety profile in patients with chronic fibrosing ILDs with a progressive phenotype treated with OFEV was consistent with that observed in patients with IPF. In addition, the following adverse events were reported in OFEV more than placebo in chronic progressive fibrosing ILD: nasopharyngitis (13% vs. 12%), upper respiratory tract infection (7% vs. 6%), urinary tract infection (8% vs. 4%), fatigue (10% vs. 6%), and back pain (8% vs. 6%).

In the phase 2 (Study 1) trial, 57 patients with SSC-ILD received OFEV 150 mg twice daily (n=228) or placebo (n=226). Patients were to receive treatment for at least 52 weeks; individual patients were treated for up to 100 weeks. The median duration of exposure was 15 months for patients treated with OFEV and 16 months for patients treated with placebo. Subjects ranged in age from 20 to 79 years (median age of 55 years). Most patients were female (75%). Patients were mostly Caucasian (67%), Asian (25%), and Black (8%). At baseline, 49% of patients were on stable therapy with prednisone. The most frequent serious adverse events reported in patients treated with OFEV, more than placebo, were interstitial lung disease (2% vs 1% placebo), and pneumonitis (2.9% vs. 0.3% placebo). Within 52 weeks, 5 patients treated with OFEV (1.7%) and 4 patients treated with placebo (1.4%) died. There was no pattern among adverse events leading to death in either treatment arm. Adverse reactions leading to permanent dose reductions were reported in 34% of OFEV-treated patients and 4% of placebo-treated patients. The most frequent adverse reaction leading to discontinuation in OFEV-treated patients was diarrhea (4%).

Includes hypertension, blood pressure increased, hypertensive crisis, and hypertensive cardiac disorders.

The following adverse reactions have been identified during postapproval use of OFEV. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during postapproval use of OFEV drug-induced liver injury (see Warnings and Precautions). A serious adverse reaction leading to death reported in 3% of patients treated with OFEV and in 3% of patients treated with placebo.

The following adverse reactions have been identified during postapproval use of OFEV drug-induced liver injury (see Warnings and Precautions). A serious adverse reaction leading to death reported in 3% of patients treated with OFEV and in 3% of patients treated with placebo.

4.7 Pregnancy: Pregnancy should be excluded with a confirmatory laboratory test. In a separate study specific to the Omicron variant, the test’s performance was similar. “How much training does it actually take for somebody to run this?” Dr. Schaffner asked. Someone licensed for testing is needed to supervise—which is why this is not a home assay—as well as a technician trained to run and interpret the results. Dr. Schaffner added. “Well just have to see how well it actually works in the real world.” Dr. Schaffner had no relevant disclosures.

5.7 Pirfenidone:

5.8 Postmarketing Experience: The following adverse reactions have been identified during postapproval use of OFEV. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse reactions have been identified during postapproval use of OFEV drug-induced liver injury (see Warnings and Precautions). A serious adverse reaction leading to death reported in 3% of patients treated with OFEV and in 3% of patients treated with placebo.

The following adverse reactions have been identified during postapproval use of OFEV drug-induced liver injury (see Warnings and Precautions). A serious adverse reaction leading to death reported in 3% of patients treated with OFEV and in 3% of patients treated with placebo.

The following adverse reactions have been identified during postapproval use of OFEV drug-induced liver injury (see Warnings and Precautions). A serious adverse reaction leading to death reported in 3% of patients treated with OFEV and in 3% of patients treated with placebo.

The following adverse reactions have been identified during postapproval use of OFEV drug-induced liver injury (see Warnings and Precautions). A serious adverse reaction leading to death reported in 3% of patients treated with OFEV and in 3% of patients treated with placebo.

The following adverse reactions have been identified during postapproval use of OFEV drug-induced liver injury (see Warnings and Precautions). A serious adverse reaction leading to death reported in 3% of patients treated with OFEV and in 3% of patients treated with placebo.
COVID-19 again the third-leading cause of U.S. deaths

BY RALPH ELLIS

COVID-19 was the third-leading cause of death in the United States in 2021 for the second straight year, with only heart disease and cancer causing more deaths, the Centers for Disease Control and Prevention (CDC) said April 22. About 693,000 people died of heart disease in 2021, with 665,000 dying of cancer and 415,000 of COVID, the CDC said, citing provisional data that might be updated later.

Unintentional injuries were the fourth-leading cause of death, increasing to 219,000 in 2021 from 201,000 in 2020. Influenza and pneumonia dropped out of the top 10 leading causes of death and suicide moved into 10th place.

Overall, about 3,458,697 deaths were reported in the United States in 2021. The age-adjusted death rate was 841.6 deaths per 100,000 people, an increase of 0.7% from 2020. The 2021 death rate was the highest since 2003, the CDC said.

About 693,000 people died of heart disease in 2021, with 665,000 dying of cancer and 415,000 of COVID.
**NETWORKS**

**Cardiac arrest; latent TB; lung cancer; and more...**

**PULMONARY VASCULAR AND CARDIOVASCULAR NETWORK**

**Cardiovascular medicine & surgery section**

Targeted temperature management (TTM) after cardiac arrest: How cool?

Recent randomized control trials, TTM2 (Dankiewicz J, N Engl J Med. 2021;384:2283) and HYPERION (Lascarrou J-B. N Engl J Med. 2019;381:2327), of therapeutic hypothermia, as opposed to normothermia, in patients who remain comatose after return of spontaneous circulation (ROSC) after cardiac arrest have produced conflicting results regarding survival and neurologic benefit. TTM2 reported no benefit to cooling to 33°C, while HYPERION found improved neurologic outcome at 90 days in patients cooled to 33°C. The European Resuscitation Council (ERC) and European Society of Intensive Care Medicine (ESICM) recently released an evidence review and guideline for adults who remain comatose after cardiac arrest (Sandroni C. Intensive Care Med. 2022;48:261). These guidelines recommend continuous monitoring of core temperature in all patients who remain comatose after cardiac arrest, and preventing fever (>37.7°C) for 72 hours, but with no recommendation of target temperature of 32°C vs 36°C.

Differences in patient populations, presenting rhythm during arrest, duration of CPR, and time to target temperature likely each contribute to the disparate conclusions of previous trials. For example, HYPERION enrolled patients with out of hospital cardiac arrest with initial nonshockable rhythms and found benefit to cooling to 33°C. In comparison, TTM2 enrolled all patients with ROSC following arrest (regardless of rhythm), including patients with in-hospital cardiac arrest and found no benefit in therapeutic cooling. Differences in patient populations are underscored by the widely differing percentage of patients with good neurologic outcome in their respective control groups: approximately 30% in the TTM2 trial and 6% in HYPERION. The guidelines leave significant room for clinical judgment in employing therapeutic cooling but encourage the continuous monitoring of core temperature and active avoidance of fever.

Fiore Mastroianna, MD  
Section Member-at-Large

**CHEST INFECTIONS & DISASTER RESPONSE NETWORK**

**Chest infections section**

Update on LTBI treatment: Ensuring success by simplifying, shortening, and completing treatment

My patient has a positive IGRA test result – what’s next?

If TB disease is ruled out by clinical, radiographic, and microbiologic assessment (if indicated), then latent TB infection (LTBI) is established, and treatment should be offered, guided by shared-decision making between provider and patient.

What options are available? While the former standard 9-month regimen of isoniazid-monotherapy can be shortened to 6 months, shorter rifamycin-based regimens are now preferred in most cases and include: 4 months rifampin daily, 3 months isoniazid plus rifampin daily, or 3 months isoniazid plus rifapentine weekly. In addition, 1 month of isoniazid plus rifapentine daily has recently been shown to be effective in people with HIV.

How to choose? Rifamycin-based regimens have been shown to have less hepatotoxicity and higher completion rates. Drug-drug interactions are of potential concern, for example, in patients receiving anticoagulation or treatment for HIV. The clinician should be aware of rifamycins causing a flu-like illness that may be treatment-limiting. In patients with known contact to drug-resistant TB, regimens are individualized.

How to monitor? Adherence and completion are the keys to success. Directly observed therapy may be indicated in certain scenarios. Baseline and monthly blood work is recommended for people with risk factors for hepatic or bone marrow toxicity. More importantly, patients should be instructed to discontinue LTBI medications and call the clinician with any new symptoms. HIV testing should be offered to all patients if status is unknown. Clinicians are encouraged to reach out to one of four regional TB Centers of Excellence for guidance (www.cdc.gov/tb/education/ tb_coe/default.htm).

Sebastian Kurz, MD, FCCP  
Amee Patrawalla, MD, MPH, FCCP  
Section Members-at-Large

**References**


**THORACIC ONCOLOGY & CHEST PROCEDURES NETWORK**

**Lung cancer section**

Adjuvant and neoadjuvant therapies in early stage lung cancer

Since the discovery of the epidermal growth factor receptor (EGFR) mutation in 2004 and the development of checkpoint blockade in 2006, personalized treatment options for non–small cell lung cancer (NSCLC) have exploded, but targeted systemic therapy medications were only recommended among patients with metastatic or locally advanced disease (Rivera MP, Matthy RA. Clin Chest Med. 2020;41[1]:ix-xi). However, in November 2020, the National Comprehensive Cancer Network (NCCN) updated guidelines to recommend EGFR testing in surgically resected stage IB-IIIA adenocarcinoma, and to consider adjuvant osimertinib in those who were mutation-positive (NCCN. Nov 2020). Interim analysis of an ongoing phase-3 trial showed 89% of patients in the osimertinib group were alive and disease-free at 24 months.

**TABLE 5**

<table>
<thead>
<tr>
<th>Daridorexant</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Absorption</strong></td>
<td></td>
</tr>
<tr>
<td>$T_{\text{max}}$ 1-2 hours</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Metabolized primarily by CYP3A4</td>
</tr>
<tr>
<td><strong>Drug interactions</strong></td>
<td>Strong-moderate CYP3A4 inhibitors/inducers</td>
</tr>
<tr>
<td><strong>Side effects</strong></td>
<td>Headache, somnolence, fatigue, dizziness, nausea, nasopharyngitis, sleep paralysis, hypnagogic/hypnopompic hallucinations, cataplexy-like symptoms, and complex sleep behaviors</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>Avoid use in patients with narcolepsy or severe hepatic impairment</td>
</tr>
</tbody>
</table>

**NETWORKS** continued on following page
Dr. Frye

11_19 thru 23_CHPH22_5.indd   20

IB-III
tcess-and-recommendations/
with NSCLC.
new chapter in the care of patients
stages of NSCLC, this is a hopeful
survival was not reached in patients
approved as neoadjuvant ther-
chemotherapy. Nivolumab is now
approved the use of
2020;383[18]:1711-23).
N Engl J Med
< .001) (Wu YL, et al.

Dr. Ghosh

IB-III
tcess-and-recommendations/
with NSCLC.
new chapter in the care of patients
stages of NSCLC, this is a hopeful
survival was not reached in patients
approved as neoadjuvant ther-
chemotherapy. Nivolumab is now
approved the use of
2020;383[18]:1711-23).
N Engl J Med
< .001) (Wu YL, et al.

NEWS FROM CHEST

Networks continued from previous page
months compared with 52% in the placebo group (hazard ratio 0.20, P
2020;383[18]:1711-23).

The FDA has also recently
approved the use of neoadjuvant and adjuvant immunotherapy in
combination with platinum-based chemotherapy. Nivolumab is now
approved as neoadjuvant ther-
chemotherapy in patients with resectable
IB-IIIA NSCLC regardless of PDL-1
status. The Checkmate-816 trial
showed increased median event-free
survival in the immunotherapy plus
chemotherapy group of 3.16 months
d vs 20.8 months in the chemother-
any-only group (FDA.gov, 2022,
Mar 4). Atezolizumab is also now
approved for adjuvant treat-
mant following resection and platinum-based
chemotherapy in patients with
stage II to IIIA NSCLC whose

PD-L1 expres-
sion on ≥ 1% of
tumor cells. Median disease-free
survival was not reached in patients in
the atezolizumab groups vs 35.3
months in the best supportive
care group (FDA.gov, 2021, Oct
15). With so many advances in the
personalized treatment among all
stages of NSCLC, this is a hopeful
new chapter in the care of patients with
NSCLC.

More information: https://
www.nccn.org/guidelines/guide-
lines-process/transparency-pro-
cess-and-recommendations/
GetFileFromFileManager/FileManager
Id=11259

Sohini Ghosh, MD
Section Member-at-Large

Diffuse Lung Disease and
Lung Transplant Network
Lung transplant section
Continuous distribution for lung
transplant: Overhauling the wait list

Determined how to allocate
the scarce resource of donor lungs
to patients is a difficult task and
evaluated continuously for poten-
tial improvement. Since 2005, in
the United States, lung transplant
recipients have been selected based
primarily on location within a
Donor Service Area and by lung
allocation score (LAS), a composit-
e score of urgency for transplant.
This was updated in 2017 to an
allocation by highest LAS within
250 nautical miles from the donor
hospital. Factors such as blood type
compatibility and height are also
considered. Implementation of the
LAS improved the sickest patients’
access to transplants while not
worsening 1-year mortality (Egan
TM. Semin Respir Crit Care Med.
2018;39[02]:126-37). Unfortunately,
geographic hard boundaries mean
a high proportion of low LAS (<50)
patients receive local donors while
high LAS patients receive national

offers or die while on the waitlist
2016;30:688-93). A new model that employs
continuous distribution has been
developed based on concerns regarding
equity and improving allocation.
This model would prioritize patients
based on factors including medi-
cal priority, efficient management
of organ placement (distance),
expected posttransplant outcomes,
and patient access (equity). By
creating a composite of these without
a geographic boundary, patients
would be considered more on
urgency within realistic constraints
of distance and outcomes.
The Organ Procurement and
Transplantation Network has offi-
cially approved continuous distribu-
tion, with implementation planned
for 2022; details regarding the
new scoring system are to be published
and further research will need to be
undertaken to determine if it meets
the goal of overall improvement in
patient access, equity, and outcomes.

Grant A. Turner, MD, MHA
Laura Frye, MD
Section Members-at-Large

Critical Care Network
Non-respiratory critical
care section
Update from the non-respiratory
critical care section

As you’ve probably noticed, there
have been some changes here at
CHEST involving the Networks.
Leadership here at CHEST has been
hard at work restructuring the net-
works to make them more closely
aligned with relevant clinical disci-
plines, and, ultimately, allow for
greater participation. I am proud
to have been given stewardship of
the new Non-Respiratory Critical
Care Section of the Critical Care
Network.

So, what exactly is Non-Respi-
atory Critical Care? Well, that’s
where I need your help. You see
this Network is meant to reflect
the needs and
wants of CHEST
members like you. We need
you, dear read-
ers, to join in
this venture and
help us guide
the content that
this section will
ultimately create for our members.
If you’re interested in critical care,
but you don’t see your particular
area of interest anywhere else in
the current structure ... guess what?
You’ve found the right place!

If you’re interested in critical care, but you don’t see your particular area of interest anywhere else in the current structure ... guess what? You’ve found the right place!
President’s report

BY DAVID SCHULMAN, MD, MPH, FCCP

There is little I enjoy more than an opportunity to get together with old friends. I write this missive on the return trip from a week of CHEST leadership meetings held last month, and I find myself filled with joy, awe, and great appreciation for the hard work our volunteers contribute to making the American College of Chest Physicians an extraordinarily productive and successful organization.

This year’s meetings meant more than any I can ever recall from the past, in the context of a return to in-person gatherings that let our members share laughs, stories, and even a game or two of laser tag in the context of celebrating good times and friendship. And while some great works were accomplished by our committees, some of which I will enumerate below, the highlight of the week was definitely the esprit de corps that was on broad display.

Our Membership Committee meeting was led by Vice-Chair Marie Budev, DO, FCCP. While this committee is tasked with the critical duty of reviewing applications for the prestigious FCCP designation, they are just as importantly tasked with promoting membership to our domestic and international colleagues. This is a challenging task, because different members prioritize the variety of benefits from CHEST differently; some focus on access to our educational offerings, both throughout the year and at our annual meeting, while others find greater value in the chance to network with colleagues from around the world and to participate in leadership in an international society. Making sure that we are helping our members realize these benefits, while also identifying (and potentially enhancing) those opportunities in which members are most interested is a challenging task and I very much enjoyed watching these folks brainstorm ways that we could further increase the value of joining CHEST for current and potential future members.

The Guidelines Oversight Committee, chaired by Lisa Moores, MD, FCCP, is responsible for the oversight of CHEST’s evidence-based guidelines. As our clinical guidelines are selected for review as part of the guideline process meet strict criteria. They receive dozens of proposals for new guidelines each year and carefully examine each one to identify the potential public health impact, to ensure the availability of literature in the space worthy of review, and to provide the opportunity to illuminate areas where there are significant clinical uncertainties, often due to new treatments or diagnostic tests.

Watching committee members meticulously debate the merits of the many good ideas received to finalize a short list of topics for guideline development in the coming year was incredibly informative and validated my longstanding perception that our members are some of the best clinical minds in the pulmonary, critical care, and sleep fields in the world.

The Professional Standards Committee (PSC), chaired by Scott Manaker, MD, PhD, FCCP, has the important duty of developing CHEST’s conflict of interest (COI) policy, as well as reviewing all potential COI among CHEST leaders and members of our guideline panels. While this may sound a little dry, the fascinating part of this meeting was the ongoing discussion of what constitutes a meaningful COI.

As one would expect, many of the best medical experts in the world have relationships with pharmaceutical and medical device companies that often seek the counsel and participation of high-performing, high-volume clinicians for research trials. CHEST has extremely strict rules with regard to COIs among its many levels of leadership, but the question of what constitutes a potentially problematic COI for the large number of folks who volunteer their time and energy to teach at one of our many courses is an interesting (albeit possibly philosophical) question. Since PSC members cannot observe every CHEST faculty interaction, we rely on our members to report on following page...
Coming together for a night of philanthropy and fun

Although attendees will be watching "The Test of the Champion" with bated breath, the upcoming Belmont Stakes Dinner and Auction on June 11 in New York City is about much more than a famous horse race. It's about community – the vibrant community of clinicians, patients, advocates, and more who support the mission to crush lung disease.

The event started small several years ago with a Sunday brunch at the home of CHEST President-Elect Doreen Addrizzo-Harris, MD, FCCP, where attendees gathered to learn more from their host about the CHEST Foundation's many initiatives. However, over the years, Dr. Addrizzo-Harris leaned on her own community of colleagues, family, friends, and patients to build an event that now boasts hundreds of attendees. But despite all that has changed, the Belmont Stakes Dinner and Auction is still dedicated to raising awareness about the CHEST Foundation and fundraising for initiatives to develop patient education and improve care.

In addition to a plated dinner, silent auction, cocktail reception, and rooftop after-party, this year's event will feature speeches from two long-time patient advocates living with chronic lung conditions, Fred Schick and Betsy Glaeser. For Dr. Addrizzo-Harris, spotlighting that unique patient perspective is particularly meaningful because the core focus of CHEST and the CHEST Foundation is to improve care and, by extension, patients' lives.

Visit foundation.chestnet.org to read a blog post with more information about Schick and Glaeser's work advocating for others with lung disease, find more details about the Belmont Stakes Dinner and Auction, and reserve your seat for this night of philanthropy and fun.

NEW CHEST Congress 2022 Dates: 27–29 June

CHEST Congress 2022 is rescheduled due to concerns over COVID-19. While the dates have changed, the location and quality of the education remain the same.

- Review relevant, engaging content from world-renowned faculty, bringing you the latest developments in chest medicine.
- Attend keynote lectures, including sessions in Italian, that convey our present scientific and technological revolution.
- Expand your knowledge, engage with international practitioners, and earn CME credits.

Register Now congress.chestnet.org

In Partnership with the Italian Delegation

This month in the journal CHEST®

Editor’s picks

BY PETER J. MAZZONE, MD, MPH, FCCP
Editor in Chief


Emerging Nonpulmonary Complications for Adults With Cystic Fibrosis. By Dr. Melanie Chin, et al.

Aspirin as a Treatment for ARDS: A Randomized, Placebo-Controlled Clinical Trial. By Dr. Philip Toner, et al.


Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. By Dr. Alessia Comes, et al.

...I’m not very hard to beat.

Until next time,
David
Introducing our new CHEST Physician editorial board member

Welcome to Corinne Young, MSN, FNP-C, FCCP who recently joined the CHEST Physician editorial board to represent and advocate for the perspective of advanced practice providers on the interdisciplinary team.

Young is a nurse practitioner and director of APP and Clinical Services for Colorado Springs Pulmonary Consultants in Colorado. She also is the founder and president of the Association of Pulmonary Advanced Practice Providers, which she created with support from CHEST staff and leaders, who encouraged her to create a community around advocating for and developing credentialing opportunities for this population.

The idea began early in Young’s career. After joining CHEST and attending educational events, she was struck by the lack of standardization in practice among APPs.

“Every time I would be at the CHEST meeting, if I happened to bump into another APP, I would assault them with questions because I didn’t know what the norm was—and come to find out, nobody did,” she said. “Our organization came out of that, and our goal is to eventually standardize the education and knowledge base of APPs.”

Because there is not an option for a national certification specifically for pulmonary medicine for APPs, Young instead attained the FCCP to demonstrate her clinical competency and knowledge. She also immersed herself in the education and community of CHEST, working on the former Clinical Research & Quality Improvement NetWork Committee and Interprofessional Team NetWork Committee, and developing patient education on asthma.

“Every time I would be at the CHEST meeting, if I happened to bump into another APP, I would assault them with questions because I didn’t know what the norm was—and come to find out, nobody did,” she said. “Our organization came out of that, and our goal is to eventually standardize the education and knowledge base of APPs.”

Supporting the Harold Amos Medical Faculty Development program

In 2020, the CHEST Foundation embarked on a bold new initiative to build trust, identify and remove barriers, and promote health care access for all in order to help fight lung disease. As part of that, we recognize that racial and ethnic minorities have been underrepresented in medical professions, contributing to these barriers to patient care.

We recognize that advocating for these groups and increasing the number of medical professors who represent people of color, ethnic minority groups, or who come from an historically disadvantaged community also increases the number of role models in our communities and can help stimulate greater interest among minority students in the health care professions. This year, CHEST is joining the American Thoracic Society (ATS) and the American Lung Association (ALA) in funding the Harold Amos Medical Faculty Development program, and the CHEST Foundation will be raising funds to support these fellowship recipients.

Harold Amos, PhD, was the first African American to chair a department, now the Department of Microbiology and Medical Genetics, of the Harvard Medical School. Dr. Amos worked tirelessly to recruit and mentor minority and disadvantaged students to careers in academic medicine and science. He was a founding member of the National Advisory Committee of the Robert Wood Johnson Foundation’s Minority Medical Faculty Development Program in 1983 and served as the Program’s National Program Director between 1989 and 1993. Dr. Amos remained active with the program until his death in 2003.

This program exists to continue Dr. Amos’s legacy and to increase the number of faculty from historically disadvantaged backgrounds who can achieve senior rank in academic medicine, dentistry, or nursing and who will encourage and foster the development of succeeding classes of such physicians, dentists, and nurse-scientists. The impact of this program is clear.

Key results

• Over the past 30 years, 241 scholars had completed all 4 years of the program (as of 2012). More than three-quarters remained in academic medicine, including 57 professors, 76 associate professors, and 56 assistant professors.
• Many program alumni have earned professional honors and become influential leaders in the health care field. For example, three direct institutions at the National Institutes of Health, and 10 have been elected to the Institute of Medicine.
• Alumni have received hundreds of awards and honors, including a MacArthur Fellowship “genius” award.
• Alumni have reached positions of influence in academia that enable them to help correct the underrepresentation of minorities in the health professions and address health disparities.

Former scholars are:

• Members of admission, intern, and faculty selection committees
• On review boards for clinical protocols and research studies
• Officers of professional societies and on editorial boards of academic journals

CHEST is proud to join with ATS and ALA to support this incredible program. We recognize that the impact on the past is only the start. By supporting this initiative, we are also looking to address the challenges of the future as the health care landscape continues to evolve. Ensuring that this program reaches the right groups and continues to promote Dr. Amos’s legacy is integral not only to the success of the program but also to aid us in being able to care for our diverse and unique patient populations.

The CHEST Foundation is raising funds to support future fellowship recipients. Join us at our next Viva la Vino wine tasting event on July 14 at 7:00 PM CT. All proceeds go to benefit this important initiative, and you can learn more about the work the Foundation does in a relaxed, social environment.
Find their path faster.

Personalize lung cancer care sooner so treatment plans can be initiated as early as possible.

Now you can access valuable blood-based genomic and proteomic insights to characterize tumor mutations and patient immune response to cancer within 72 hours. IQLung™ testing from Biodesix® helps you optimize personalized treatment decisions faster, to ensure each patient has the best chance to fight lung cancer.

Move each patient onto the right path for them.

Take the first step at Biodesix.com/IQLung